MedTrace Logo

IntErnational Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN

NCT01705080 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 276

Last updated 2021-05-27

Study results available
· View outcomes & findings →

Summary

The purpose of this post market clinical investigation is to further evaluate the safety and performance of the EnligHTN™ Renal Denervation System in the treatment of patients with uncontrolled hypertension.

Conditions

Interventions

DEVICE

EnligHTN

Renal artery ablation with EnligHTN system used for all groups

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Melvin Lobo, MBChB PhD · NIHR Barts Cardiovascular Biomedical Research Unit

  • Stephen Worthley, MB BS PhD · Royal Adelaide Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-17
Primary Completion
2017-04-30
Completion
2019-11-27

Countries

  • Australia
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • New Zealand
  • Norway
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01705080 on ClinicalTrials.gov